| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ropivacaine Readyfusor® |
| Brand | Ropivacaine Readyfusor® |
| Indication | For acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion. |
| Assessment Process | |
| Rapid review commissioned | 09/11/2018 |
| Rapid review completed | 13/12/2018 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Ropivicaine Readyfusor not be considered for reimbursement at the submitted price. |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.